Calliditas Q4: Steady US launch support - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Calliditas Q4: Steady US launch support - Redeye

{newsItem.title}

Calliditas recorded Q4 Tarpeyo sales of SEK 169m which is slightly below our and the markets expectations. The number of unique (US) subscribers has increased by 34% to 642 in Q4 (from Q3). Calliditas provides the first full year Tarpeyo sales guide for 2023 (strict US product sales) and this is a USD range of USD 120m to 150m. The high range of this guide is very close to Redeye and the market consensus ahead of the full year.

Länk till analysen i sin helhet: https://www.redeye.se/research/883527/calliditas-q4-steady-us-launch-support?utm_source=finwire&utm_medium=RSS

Nyheter om Calliditas Therapeutics

Läses av andra just nu

Om aktien Calliditas Therapeutics

Senaste nytt